INSILICO (03696) has reached a milestone in its collaboration with TAIJING, with the external authorization of the CKD anemia new drug ISM4808, completing the enrollment of the first subject in the Phase I clinical trial and administering the drug.

INSILICO (03696) announced that the company has reached the first milestone agreement for its innovative drug ISM4808 for chronic kidney disease (CKD) anemia, which was previously licensed to Taijiong (stock code: 4157.TWO). Recently, Taijiong has successfully completed the enrollment and dosing of the first subject in the Phase I clinical trial of the AI-driven PHD inhibitor. The clinical trial is a randomized, double-blind, placebo-controlled study, which includes single-dose (SAD) and multiple-dose (MAD) parts, aiming to evaluate the safety, tolerability, and pharmacokinetic characteristics of ISM4808 in healthy adults. It is reported that INSILICO reached a pipeline authorization agreement with Taijiong for the ISM4808 project in December 2025. According to the agreement, Taijiong has exclusive development, commercialization, and sublicensing rights for ISM4808 in the Greater China region (including mainland China, Hong Kong, Macau, and Taiwan). INSILICO, on the other hand, receives an upfront payment, milestone payments based on development and sales, as well as tiered royalty payments based on net sales, with the total transaction amounting to tens of millions of dollars.